Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
Condition:   Neurofibromatosis 1 Interventions:   Diagnostic Test: Blood draw;   Other: FACIT-F and Pain Scales Sponsor:   University of Arkansas Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Conditions:   Neurofibromatosis 1;   Plexiform Neurofibroma;   NF1 Interventions:   Drug: Test group (Group A): FCN-159 8 mg, orally, once daily;;   Drug: Control group (Group B): Placebo, orally, once daily; Sponsor:   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
Condition:   Neurofibromatosis 1 Interventions:   Diagnostic Test: Blood draw;   Other: FACIT-F and Pain Scales Sponsor:   University of Arkansas Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Conditions:   Neurofibromatosis 1;   Plexiform Neurofibroma;   NF1 Interventions:   Drug: Test group (Group A): FCN-159 8 mg, orally, once daily;;   Drug: Control group (Group B): Placebo, orally, once daily; Sponsor:   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
Condition:   Neurofibromatosis 1 Interventions:   Diagnostic Test: Blood draw;   Other: FACIT-F and Pain Scales Sponsor:   University of Arkansas Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Conditions:   Neurofibromatosis 1;   Plexiform Neurofibroma;   NF1 Interventions:   Drug: Test group (Group A): FCN-159 8 mg, orally, once daily;;   Drug: Control group (Group B): Placebo, orally, once daily; Sponsor:   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
Condition:   Neurofibromatosis 1 Interventions:   Diagnostic Test: Blood draw;   Other: FACIT-F and Pain Scales Sponsor:   University of Arkansas Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Conditions:   Neurofibromatosis 1;   Plexiform Neurofibroma;   NF1 Interventions:   Drug: Test group (Group A): FCN-159 8 mg, orally, once daily;;   Drug: Control group (Group B): Placebo, orally, once daily; Sponsor:   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
Condition:   Neurofibromatosis 1 Interventions:   Diagnostic Test: Blood draw;   Other: FACIT-F and Pain Scales Sponsor:   University of Arkansas Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Conditions:   Neurofibromatosis 1;   Plexiform Neurofibroma;   NF1 Interventions:   Drug: Test group (Group A): FCN-159 8 mg, orally, once daily;;   Drug: Control group (Group B): Placebo, orally, once daily; Sponsor:   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

Improvement of synaptic plasticity and cognitive function in RASopathies —a monocentre, randomized, double-blind, parallel-group, placebo-controlled, cross-over clinical trial (SynCoRAS)
DiscussionThe study is targeting impairments in synaptic plasticity and cognitive impairment, one of the main health problems of patients with RASopathies. Recent first results with LOV in patients with NF1 have shown an improvement in synaptic plasticity and cognition. Within this clinical trial, it is investigated if these findings can be transferred to patients with NS. LTG is most likely a more effective and promising substance improving synaptic plasticity and, consecutively, cognitive function. It is expected that both substances are improving synaptic plasticity as well as alertness. Changes in alertness may be a pr...
Source: Trials - June 6, 2023 Category: Research Source Type: clinical trials

Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1
Conditions:   Neurofibromatosis 1;   Malignant Peripheral Nerve Sheath Tumor (MPNST) of Soft Tissue (Diagnosis);   Atypical Neurofibroma Intervention:   Diagnostic Test: Whole Body Magnetic Resonance Imaging Sponsor:   Johns Hopkins University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 10, 2023 Category: Research Source Type: clinical trials